FNY Managed Accounts’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

FNY Managed Accounts’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	$0	Hold	127	–	–	﹤0.01%	983
2017 Q4	$1K	Sell	127 -1,957	-94%	-$18.2K	﹤0.01%	633
2017 Q3	$23K	Buy	+2,084	New	+$21.9K	0.03%	320
2016 Q2	–	Sell	-1,271	Closed	-$83.7K	–	482
2016 Q1	$83.7K	Buy	+1,271	New	+$66.3K	0.15%	108

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FNY Managed Accounts's MACK Position: Q1 2018 in Review

FNY Managed Accounts held its Merrimack Pharmaceuticals, Inc. (MACK) position steady in Q1 2018 at 127 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #983.

FNY Managed Accounts first reported a position in MACK in Q1 2016 and has held it in 4 quarters since. The position peaked at $83.7K in Q1 2016. 81 funds tracked by Wall St. Rank hold MACK as of Q1 2018.

FNY Managed Accounts held 127 shares of Merrimack Pharmaceuticals, Inc. worth $0 as of Q1 2018.
FNY Managed Accounts left its Merrimack Pharmaceuticals, Inc. share count unchanged in Q1 2018.
Merrimack Pharmaceuticals, Inc. made up ﹤0.01% of FNY Managed Accounts's portfolio in Q1 2018, its #983 holding.
FNY Managed Accounts first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2016 and has held it in 4 quarters since.
FNY Managed Accounts's Merrimack Pharmaceuticals, Inc. position peaked at $83.7K in Q1 2016.
81 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2018.

Based on FNY Managed Accounts's 13F filing for Q1 2018, filed 18 Apr 2018.